MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1177/10600280251373074

Медицинская библиотека · The Annals of pharmacotherapy · 2025

Ivabradine Use for Arrhythmias in Children.

Foote David, Le Monica, Johnson Peter N, Miller Jamie L, Behere Shashank, Stephens Katy S

СтатьяПеревод в очереди

Аннотация

BACKGROUND

Ivabradine is a hyperpolarization-activated cyclic nucleotide-gated channel blocker that has an off-label indication for arrhythmias in pediatric patients.

OBJECTIVES

The primary objective was identification of the line of therapy and type of arrhythmia for which ivabradine was initiated. The secondary objective was to evaluate the initial and peak ivabradine doses, tolerance in partially fed patients (i.e., patients not receiving full feeds at the time of ivabradine initiation), number of patients continued home on ivabradine, concomitant drug interactions with a class C, D, or X classification, and adverse effects.

METHODS

A retrospective study of hospitalized patients <18 years of age receiving ivabradine for arrhythmias between January 1, 2021 and November 30, 2023. Data variables included demographics, ivabradine dosing regimens, concomitant anti-arrhythmic medications, percentage of ivabradine course while receiving full enteral feeds, concomitant medications with drug-drug interactions, and adverse effects (bradycardia [defined as <100 beats/min in neonates and <50 beats/min in infants and children], atrial fibrillation, vision changes, and emesis attributed to ivabradine).

RESULTS

Seventeen patients were included. The most frequent arrhythmia indication was atrial tachycardia and ivabradine was most frequently used as a third-line anti-arrhythmic. Ten (58.8%) received ivabradine despite not being on full enteral feeds. The median initial and peak ivabradine doses were 0.05 mg/kg/dose and 0.07 mg/kg/dose, respectively, and it was most frequently administered every 12 hours. Only 1 patient required a dose decrease for a noted adverse effect. Most patients (94.1%) had a Class C drug-drug interaction, and 3 had a Class X interaction. Ten (58.8%) were discharged home on ivabradine.

CONCLUSIONS AND RELEVANCE: Ivabradine was safe and effective as additive therapy for the treatment of pediatric arrhythmias. Larger studies of ivabradine use in pediatric arrhythmias are needed.

Для цитирования: Foote David, Le Monica, Johnson Peter N, Miller Jamie L, Behere Shashank, Stephens Katy S. Ivabradine Use for Arrhythmias in Children.. The Annals of pharmacotherapy. 2025. DOI: 10.1177/10600280251373074.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.